Moderate hypofractionated helical tomotherapy for older patients with localized prostate cancer: long-term outcomes of a phase I–II trial

Moderate hypofractionated helical tomotherapy for older patients with localized prostate cancer: long-term outcomes of a phase I–II trial

Our previous study showed that two different regimens of moderate hypofractionated radiotherapy (HFRT) delivered with helical tomotherapy (HT) are well tolerated in older prostate cancer patients. We provide a longterm efficacy and toxicity after > 7 years of follow-up.

Bibliographic Details
Main Authors: Cui Di, Du Lei, Yu Wei, Cai Boning, Meng Lingling, Yang Jun, Luo Yanrong, Chen Jing, Ma Lin
Format: Article
Language:English
Published: Sciendo 2022-03-01
Series:Radiology and Oncology
Subjects:
helical tomotherapy
radiation dose hypofractionation
progression-free survival
follow-up studies
prostatic neoplasms
adenocarcinoma
Online Access:https://doi.org/10.2478/raon-2022-0011

Internet

https://doi.org/10.2478/raon-2022-0011

Similar Items